Clinical Trial Update: First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial of IDRX-42 for metastatic and/or unresectable gastrointestinal stromal tumors (GIST) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Gastrointestinal Neoplasms
• Gastrointestinal Stromal Tumor

Drugs mentioned

• IDRX-42 (GSK6042981)

Snippet

Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC | Conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST) | Phase 1 | Status: RECRUITING